Abstract: The invention relates to a pharmaceutical composition of polyethylene glycol in solid powder form contained within a polymer bag having an opening. The invention also provides a method for administering a pharmaceutical composition of polyethylene glycol in solid powder form. The method includes providing a polymer bag containing the pharmaceutical composition of polyethylene glycol and adding a fluid to the bag. The polymer bag has a threaded spout and a cap threadably mountable to the spout. The threaded spout forms a passageway to an interior volume of the bag.

Abstract: An aqueous ophthalmic solution containing a relatively high concentration of olopatadine in solubilized form is provided. The solution comprises a combination of at least two non-ionic surfactants and is essentially devoid of cyclodextrins. The solution is useful for providing enhanced relief from symptoms of ocular allergic disorders (e.g. conjunctivitis).

Abstract: The present invention is directed to a new impurity of famotidine, process for preparing and isolating it. The invention is further related to analytical methods of its identification, synthesis and characterization.

Abstract: An aqueous ophthalmic solution containing relatively high concentration of olopatadine in solubilized form and process for making such solution is provided. The process for preparing the aqueous ophthalmic solution comprises a step of sizing olopatadine particles, preferably by using a microfluidizer, a ball mill or a colloidal mill. The solution is useful for providing enhanced relief from symptoms of ocular allergic disorders (e.g. conjunctivitis).

Abstract: A topical oil-in-water composition of ivermectin is provided. The topical oil-in-water composition contains an oily phase, an aqueous phase and a surfactant emulsifier. The emulsion is essentially devoid of any solvents or propenetrating agents for ivermectin and any gelling agent.

Abstract: A topical gel composition of ivermectin is provided. The topical gel composition contains a pharmaceutically acceptable glycol and a pharmaceutically acceptable gelling agent. The composition is essentially devoid of any alcohol.

Abstract: A topical lotion composition of ivermectin is provided. The topical lotion composition contains a pharmaceutically acceptable alcohol and a pharmaceutically acceptable gelling agent. The composition is essentially devoid of any surfactant.

Abstract: A topical water-in-oil composition of ivermectin is provided. The topical water-in-oil composition contains an oily phase, an aqueous phase and a surfactant emulsifier. The emulsion is essentially devoid of any glycols.

Abstract: A topical solution composition of ivermectin is provided. The topical solution composition contains a pharmaceutically acceptable alcohol and a pharmaceutically acceptable gelling agent. The composition is essentially devoid of any glycols, glycerine or ether and esters thereof.

Abstract: The invention relates to an ophthalmic emulsion composition of cyclosporine in the form of oil-in-water emulsion. The emulsion remains stable at 25° C. for at least 6 months or at 45° C. for at least 45 days. The composition is useful for treating a dry eye condition or glaucoma, and preferably for increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

Abstract: The invention relates to an ophthalmic emulsion composition of cyclosporine in the form of an oil-in-water emulsion. The emulsion remains stable at 25° C. for at least 6 months or at 45° C. for at least 45 days. The composition is useful for treating a dry eye condition or glaucoma, and preferably for increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

Abstract: The invention refers to an ophthalmic emulsion composition of cyclosporine in the form of an oil-in-water emulsion. The emulsion remains stable at 25° C. for at least 6 months or at 45° C. for at least 45 days. The composition is useful for treating a dry eye condition or glaucoma, and preferably for increasing the tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

Abstract: A novel combination of two antifungal agents is provided. The combination contains ciclopirox and a triazole containing antifungal agent or salts thereof. The invention also provides a method of treating onychomycosis using said antifungal agent combination.

Abstract: A pharmaceutical composition of bupropion or salts thereof and naltrexone or salts thereof is provided. The composition comprises bupropion and naltrexone in a single matrix core. The two active ingredients are not physically separated and neither represents a separate layer. A method of manufacturing the composition is also provided.

Abstract: A topical pharmaceutical gel composition of diclofenac sodium suitable for twice daily application is provided. The topical gel composition contains at least about 10% w/w of diclofenac sodium and twice daily application of the composition provides relief from pain or inflammation comparable to that achieved with 4 times daily application of diclofenac sodium 1% or 3% topical gel.

Abstract: A topical pharmaceutical gel compositions of diclofenac sodium, is provided. The topical gel composition contains at least about 10% w/w diclofenac sodium and is suitable for twice daily application.

Abstract: The present invention provides compositions and methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The composition can improve patient compliance, and thus, efficacy of the preparation. Specifically, the composition of the invention is palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation liquid taste significantly less salty.

Abstract: Oral pharmaceutical compositions of treprostinil, a prodrug, or a pharmaceutically acceptable salt thereof are provided. The compositions possess absolute oral bioavailability of greater than 10% and achieve circulating concentrations when administered orally. Methods of treating prostacyclin responsive conditions including pulmonary arterial hypertension (PAH) by administering such compositions also are provided.

Abstract: A novel and improved aqueous nasal spray composition comprising a combination of corticosteroids and antihistaminic agents is provided. The composition is characterized by containing chitosan and/or polycarbophil as a bio-adhesive or mucoadhesive agent. The invention also provides a method of alleviating or treating a corticosteroid or antihistaminic agent responsive condition or disease by topically administering said aqueous nasal spray composition to the nasal cavity.

Abstract: A pharmaceutical composition comprising granules of sodium picosulfate, citric acid, magnesium oxide and sodium bicarbonate is provided. The composition has fewer or none of the side effects of those side effects associated with known sodium picosulfate purgatives. The composition also ensures homogeneity or content uniformity of the ingredients and is prepared by a simple manufacturing process.